Nexstim Plc · OMXHEX:NXTMH
Nexstim — H1 2022 Earnings Presentation
9 slides from Nexstim's earnings presentation, Aug 12, 2022
Slide 1: Nexstim - Personalized brain diagnostics and therapy
Nexstim - Personalized brain diagnostics and therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H1 2022 Financial Results Webinar, 12 August 2022 Nexstim Oyj
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating growth-oriented medical technology company. MISSION VISION VALUES We enable personalized and With our technological know-how Science and clinical evidence effective therapies and and superior services, diagnostics for challenging we ensure the b
Slide 4: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. • Population aging and a significant decline in the Aging population working-age and able population in Western countries • Brain diseases increase with aging T
Slide 5: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS Diagnostics (Navigated Over 210 Pre-surgical CE marked FDA approved Business Brain systems sold mapping Stimulation) FDA approved Depression CE marked with existing NBT® Over 50 reimbursement Therapy (Na
Slide 6: Business and Financial Summary H1 2022
Nexstim Business and Financial Summary H1 2022 • Nexstim’s historically best half year measured by net sales and operating profit • H1 2022 was the first positive Operating result in the history of the company • Business has continued to grow rapidly despite the tense global political situation caus
Slide 7: H1 2022 Key Financials
H1 2022 Key Financials Key Financials of the Group Total net sales 6.8M€ +130% 1–6/2022 1–6/2021 1–12/2021 • NBS net sales 2.1M€ +19% EUR in thousands Change-% 6 months 6 months 12 months • NBT net sales 4.7M€ +290% • System sales 1.8M€ +11% Net Sales 6,793.0 2,958.6 129.6 6,397.5 • Recurring revenu
Slide 8: Key Strategic Objectives 2022
Nexstim Key Strategic Objectives 2022 Continued profitable net sales growth, leading into our first operating 1 profit-making financial year, while also minimizing future capital needs Expansion of Nexstim’s network of exclusive neuroscience center 2 partner clinics, especially in the United States
Slide 9: Thank you!
Thank you! Follow us on social media: Nexstim Oyj Nexstim Plc Public Presentation 9